The FDA approved drug locaserin is a serotonin 2C receptor (5HT2C) agonist, validating the 5HT2C as an anti‐obesity drug target (Miller, 2005). The gene discussed is HTR2C; the disease is obesity due to melanocortin 4 receptor deficiency.